课题基金 / 基金详情

Signaling mechanisms and functions related to patho-physiology of vascular, lung and blood systems

Signaling mechanisms and functions related to patho-physiology of vascular, lung and blood systems
与血管、肺和血液系统病理生理学相关的信号传导机制和功能
批准号:
10570974
负责人:
Dianqing Wu
金额:
$91.23万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-02-01 至 2024-06-30

项目摘要

项目成果

Dianqing Wu的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: My laboratory is interested in understanding molecular basis and functions for two signaling pathways that use seven transmembrane receptors in their signaling transduction. One of the pathways is mediated by G protein-coupled receptors, and the other is activated by Wnt proteins. We have been using a combination of biochemical, molecular and cell biological, transgenic, genomic, proteomic, structural and chemical biological approaches to discover novel signaling mechanisms and investigate their functions in vitro and in vivo. In this R35 application, I intend to streamline our current four research projects that are pertinent to NHBLI missions under one funding mechanism. Two of the projects are current funded by NHBLI. These four projects are: 1) To test the hypothesis that the initial break of the symmetry may arise from PM PI4P polarization caused by plasma membrane deformation as the result of cell attachment. Polarized PM PI4P defines the “uropod” and thus the initial cellular polarity, upon which further polarization stimulated by chemoattractants is extended. 2) To investigate the sustained signaling pathway for regulation of fibroblast migration and its therapeutic potential in treating pulmonary fibrosis. 3) To Investigate the hypothesis that increased exocytosis is a pathogenic basis for CCM disease. 4) To investigate MEKK3 as being a negative regulator of NADPH oxidase 2 (NOD2) and potential therapeutic target for acute respiratory distress syndrome. Each of the project is highly innovative and would exert a strong impact in their respective field. In addition, we are generating the new leads coming from these high risk/high reward studies that include functional genomic screens based on the CRISPR/Cas9 and RNAi technologies. Thus, this R35 mechanism would not only allow streamlining our grant application and management so that we can better focus our effort on research, but also afford us the flexibility to fully and efficiently pursue the new leads coming from these high risk/high reward studies. Our track record strongly indicates our readiness, capability, and success to pursue subjects that we deem to be of high-impact even though they fall outside our initial intents.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3.
Pazopanib通过抑制MAP3K2和MAP3K3来改善急性肺损伤。
DOI: 10.1126/scitranslmed.abc2499
发表时间: 2021-04-28
期刊: Science translational medicine
影响因子: 17.1
作者: [Yuan Q, Basit A, Liang W, Qu R, Luan Y, Ren C, Li A, Xu X, Liu X, Yang C, Kuo A, Pierce R, Zhang L, Turk B, Hu X, Li F, Cui W, Li R, Huang D, Mo L, Sessa WC, Lee PJ, Kluger Y, Su B, Tang W, He J, Wu D]
通讯作者: Wu D
DOI: 10.1016/j.devcel.2019.02.023
发表时间: 2019-04
期刊: Developmental cell
影响因子: 11.8
作者: [Chunguang Ren;Qianying Yuan;M. Braun;Xia Zhang;B. Petri;Jiasheng Zhang;Dongjoo Kim;J. Guez-Haddad;Wenzhi Xue;Weijun Pan;R. Fan;P. Kubes;Zhaoxia Sun;Y. Opatowsky;F. Polleux;E. Karatekin;Wenwen Tang;Dianqing Wu]
通讯作者: Chunguang Ren;Qianying Yuan;M. Braun;Xia Zhang;B. Petri;Jiasheng Zhang;Dongjoo Kim;J. Guez-Haddad;Wenzhi Xue;Weijun Pan;R. Fan;P. Kubes;Zhaoxia Sun;Y. Opatowsky;F. Polleux;E. Karatekin;Wenwen Tang;Dianqing Wu
shRNA-Induced Gene Knockdown In Vivo to Investigate Neutrophil Function.
shRNA 诱导体内基因敲低以研究中性粒细胞功能。
DOI: 10.1007/978-1-4939-3480-5_13
发表时间: 2016
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Basit,Abdul, Tang,Wenwen, Wu,Dianqing]
通讯作者: Wu,Dianqing
DOI: 10.3389/fphar.2021.667361
发表时间: 2021
期刊: Frontiers in pharmacology
影响因子: 5.6
作者: [Han S, Zhang H, Yi M, Liu X, Maegawa GHB, Zou Y, Wang Q, Wu D, Ye Z]
通讯作者: Ye Z
A novel signaling mechanism for LRP5
  • 批准号:
    10706591
  • 项目类别:
  • 资助金额:
    $53.56万
  • 财政年份:
    2022
  • 负责人:
    Dianqing Wu
  • 依托单位:
A novel signaling mechanism for LRP5
  • 批准号:
    10527478
  • 项目类别:
  • 资助金额:
    $54.65万
  • 财政年份:
    2022
  • 负责人:
    Dianqing Wu
  • 依托单位:
Signaling mechanisms and functions related to patho-physiology of vascular, lung and blood systems
  • 批准号:
    9244290
  • 项目类别:
  • 资助金额:
    $91.23万
  • 财政年份:
    2017
  • 负责人:
    Dianqing Wu
  • 依托单位:
DKK2 regulates NK activation and tumor immunity
  • 批准号:
    10064071
  • 项目类别:
  • 资助金额:
    $51.33万
  • 财政年份:
    2017
  • 负责人:
    Dianqing Wu
  • 依托单位: